Market Overview

UPDATE: Stifel Nicolaus Cuts PT to $37 on Theravance Ahead of March PADAC Meeting

Related THRX
Theravance Announces Initiation of Phase 2b Study With TD-4208, an Investigational LAMA for the Treatment of COPD
Glaxo/Theravance Update on COPD Drugs - Analyst Blog

Stifel Nicolaus maintained Theravance (NASDAQ: THRX) with a Buy rating and lowered the price target from $40.00 to $37.00.

Stifel Nicolaus commented, "We expect the release of BREO briefing docs (likely March 4th/5th) and subsequent PADAC meeting to likely generate a meaningful amount of volatility in the stock. However, we continue to like the risk/reward at current levels and remain Buy-rated with $37 target price."

Theravance closed at $21.60 on Tuesday.

Posted-In: Stifel NicolausAnalyst Color Price Target Analyst Ratings

 

Most Popular

Related Articles (THRX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free